Latest News

Two months after the approval of the first biosimilar to infliximab, another Biologics License Application is now under FDA review.
The smallest overall increase in the MMI in 15 years is masked by the fact that employees are bearing an increasingly large share of healthcare costs.
A recent study showed patients with type 2 diabetes did better if given the combination therapy at the outset than if given 1 of the components as monotherapy.
California’s approach to the healthcare marketplace, Covered California, has successfully held down premium costs because it has authority to select health insurers.
A survey conducted by MaPS/Millward Brown Analytics, on behalf of Memorial Sloan Kettering Cancer Center, has identified multiple concerns of American consumers with cancer clinical trial participation, which could be responsible for the dismal 4% national enrollment rate in clinical trials.
What we're reading, May 24, 2016: Doubt grows about the stability of the Anthem-Cigna merger; use of e-cigarettes and vaping devices stalls in the US; and drugmakers are cautious about developing a Zika virus.
A phase 1 study in 225 patients diagnosed with breast cancer, non-small cell lung cancer, glioblastoma, melanoma, or colorectal cancer has concluded that abemaciclib, a selective inhibitor of the cell cycle regulators CDK4/6, has single-agent activity in specific tumor types.
For patients with private drug insurance plans, out-of-pocket expenses, not the timing of patient reimbursements, have a greater affect on medication adherence.
Finding diabetes and treating it early can prevent high healthcare costs in the long term, the authors day.
The updated label reflects research that shows how hard it is to consume key nutrients and maintain calorie limits in a diet overwhelmed by sugar. The label will be a legacy of First Lady Michelle Obama's focus on better nutrition to combat childhood obesity.
An Oklahoma-based non-profit hospital is the latest medical facility to sue pharmaceutical giant Genentech,accusing the company of shipping less than the labeled claim of the anticancer drug trastuzumab (Herceptin) in each multi-dose vial.
What we're reading, May 23, 2016: Oklahoma governor vetoes bill banning abortion; the FDA approved a new nutrition label highlighting sugar added; and 7 years after death panels, conversations on end-of-life planning are becoming more common.
One year after being hospitalized for heart failure, one-third of patients had not returned to work, according to a study presented at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure.
Only a small percentage of eligible employees used an online price transparency tool designed to help them understand healthcare spending. Furthermore, use of the tool was not associated with a decrease in spending.

From the Journals

Now that Medicare is poised to pay for the Diabetes Prevention Program, the next question is how to make it scalable.
How does the largest payer in a state with a large senior population respond to the rising need for diabetes care and prevention?
The authors discuss a simple strategy for payers to ensure more patients with type 2 diabetes achieve control of A1C.
A recent Diabetes Care study found flaws in Medicare's competitive bidding program for diabetes test strips. Two of that study's co-authors discuss the findings and why CMS should suspend the bidding program.
The author, who has lived with type 1 diabetes for more than 50 years, shares his account of a successful appeal of Medicare's policy of refusing to pay for continuous glucose monitoring (CGM.)
This review examines the breadth of published work on interventions addressing nonmedical determinants of health that are supported by Medicaid managed care organizations.
Hybrid approaches allow for clinician input into case finding for care management, but training and monitoring is required to protect against unintentional biases.
The authors surveyed physicians regarding “Choosing Wisely” and hypothesized drivers of overuse, finding high reported prevalence of hypothesized drivers of overuse and widespread support for cost-consciousness.
Biosimilars in the United States may demonstrate higher discounts and cost reduction than current estimates.
Featured Content
Diabetes Compendium
Oncology Compendium
Reimbursement Compendium
HF Compendium

Most Popular

Upcoming Partner Events
May 21-25, 2016
Washington, DC, USA
16-17 June, 2016
Philadelphia, US
August 17-18, 2016
Philadelphia, PA
August 23-24, 2016
Chicago, IL
October 19-20, 2016
Scottsdale, AZ

AJMC Strategic Alliance